Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus chemotherapy as perioperative treatment for locally advanced oral squamous cell carcinoma
ChiCTR2500115666Phase 3Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sintilimab in Oral Mucosal Carcinoma (2 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: 2-year event-free survival. Started Dec 2025; status: recruiting.
02
Drugs
sintilimab
03
Conditions
Oral Mucosal Carcinoma
Beyond the preview
Go deeper on ChiCTR2500115666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115666.